Daniel J. Stein
Medical College of Wisconsin, USA
Title: Positioning of Biologics in Crohn’s Disease: A New Balancing Act
Biography
Biography: Daniel J. Stein
Abstract
Management of Crohn’s disease is a topic that is constantly changing and evolving. Balancing the risks of therapy with the potential complications of untreated Crohn’s disease is at the forefront of every clinician’s mind. However, knowing when to start biologic therapy is often a difficult problem for many clinicians. Additionally with the advent of anti-integrin therapy the choices have been expanded and the conversation with patients is more complicated. My talk will focus on how to best identify patients with moderate to severe Crohn’s disease who are candidates for biologic therapy. Then it will discuss the potential side effects of these medications and how to best minimize these. It will then discuss the data that led to the recent approval of vedolizumab in the United States as well as the side effect profile of medication. Lastly it will discuss the positioning of vedolizumab in relation to anti-TNF therapy and how to balance the risks of the different therapies with expected benefits.